Objective:To analyze the effect of β-blocker use in coronary atherosclerotic heart disease therapy.Methods:Choose between hospital from February 2013 to August 2014 coronary atherosclerotic heart disease treated 64 cases as observed object of this study,in accordance with the principles of randomized controlled study will be divided into two groups,each with 32 cases in the control group conventional treatment for patients with coronary heart disease clinical study group receivedβ-blocker therapy on the basis of the control group.Comparison of the clinical efficacy of the two groups of patients,and compared the two groups of patients with adverse reactions were observed to happen.Results:The study group clinical total effective rate of 90.63%,higher than 78.13%,the differences were statistically analyzed significant (O<0.05),and the incidence of adverse reac-tions between the two groups showed no significant difference (O>0.05).Conclusion:This study showed that,β-blockers for patients with coronary heart disease treatment,to improve the clinical efficacy,while still not increase adverse reactions,it is worthy of clinical application.%目的：研究分析β受体阻滞剂在冠状动脉粥样硬化性心脏病治疗中的应用效果。方法：随机选取本院2013年2月至2014年8月间收治的冠状动脉粥样硬化性心脏病患者64例作为本次研究的观察对象，按照随机分组对照原则将其分成研究组和对照组，各有32例，对照组患者实施冠心病临床常规治疗，研究组在对照组的基础上予以β受体阻滞剂治疗。比较两组患者的临床疗效，并对比观察两组患者的不良反应发生情况。结果：结果显示，研究组患者的临床总有效率为90．63％，高于对照组78．13％，且组间差异经统计学分析存在显著性（O＜0．05）；研究组药物不良反应略高于对照组，但经统计学分析差异无统计学意义（O＞0．05）。结论：研究表明，β受体阻滞剂用于冠状动脉粥样硬化性心脏病患者治疗中，在提高临床疗效的同时，还不至于增加不良反应，其值得临床推广应用。
展开▼
